Session

IBD (Posters)

QUALITY OF LIFE, FECAL CALPROTECTIN AND ENDOSCOPIC DISEASE ACTIVITY: A STUDY OF CORRELATION IN INFLAMMATORY BOWEL DISEASE
QUALITY OF LIFE, FECAL CALPROTECTIN AND ENDOSCOPIC DISEASE ACTIVITY: A STUDY OF CORRELATION IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY
COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY

IBD (Posters)  et al.

INFLAMMATORY BOWEL DISEASE AND CONCOMITANT ENDOMETRIOSIS: FREQUENCY AND CHARACTERISTICS IN A MULTIDISCIPLINARY APPROACH
INFLAMMATORY BOWEL DISEASE AND CONCOMITANT ENDOMETRIOSIS: FREQUENCY AND CHARACTERISTICS IN A MULTIDISCIPLINARY APPROACH

IBD (Posters)  et al.

COMBINATION THERAPY IN IBD PATIENTS: DO WE NEED TO MAXIMIZE THE DOSE OF AZATHIOPRINE?
COMBINATION THERAPY IN IBD PATIENTS: DO WE NEED TO MAXIMIZE THE DOSE OF AZATHIOPRINE?

IBD (Posters)  et al.

LOCAL APPLICATION OF AUTOLOGOUS PLATELET-RICH PLASMA IS SAFE AND EFFECTIVE IN TREATMENT OF COMPLEX CROHN`S PERIANAL FISTULAE - RESULTS FROM SINGLE CENTER PILOT STUDY
LOCAL APPLICATION OF AUTOLOGOUS PLATELET-RICH PLASMA IS SAFE AND EFFECTIVE IN TREATMENT OF COMPLEX CROHN`S PERIANAL FISTULAE - RESULTS FROM SINGLE CENTER PILOT STUDY

IBD (Posters)  et al.

FECAL CALPROTECTIN AND DRUG LEVELS AT WEEK 14 PREDICT LONG-TERM RESPONSE OF VEDOLIZUMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASES: A REPORT FROM THE PROSPECTIVE, MULTI-CENTRE VEDOKIDS STUDY
FECAL CALPROTECTIN AND DRUG LEVELS AT WEEK 14 PREDICT LONG-TERM RESPONSE OF VEDOLIZUMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASES: A REPORT FROM THE PROSPECTIVE, MULTI-CENTRE VEDOKIDS STUDY

IBD (Posters)  et al.

COMPARISON STUDY BETWEEN PROMONITOR QUICK IFX AND QUANTUM BLUE® INFLIXIMAB FOR THE QUANTIFICATION OF INFLIXIMAB LEVELS
COMPARISON STUDY BETWEEN PROMONITOR QUICK IFX AND QUANTUM BLUE® INFLIXIMAB FOR THE QUANTIFICATION OF INFLIXIMAB LEVELS

IBD (Posters)  et al.

EFFICACY AND SAFETY OF USTEKINUMAB IN CROHN'S DISEASE: A REAL-WORLD STUDY FROM THE UNITED KINGDOM
EFFICACY AND SAFETY OF USTEKINUMAB IN CROHN'S DISEASE: A REAL-WORLD STUDY FROM THE UNITED KINGDOM

IBD (Posters)  et al.

SWITCHING FROM ORIGINATOR ADALIMUMAB (HUMIRA®) TO BIOSIMILAR (HULIO®) IN AN IBD POPULATION
SWITCHING FROM ORIGINATOR ADALIMUMAB (HUMIRA®) TO BIOSIMILAR (HULIO®) IN AN IBD POPULATION

IBD (Posters)  et al.

SYSTEMATIC REVIEW AND META-ANALYSIS: SAFETY OF VEDOLIZUMAB DURING PREGNANCY IN FEMALE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SYSTEMATIC REVIEW AND META-ANALYSIS: SAFETY OF VEDOLIZUMAB DURING PREGNANCY IN FEMALE PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

BODY MASS INDEX DOES NOT IMPACT CLINICAL EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE IM-UNITI TRIAL
BODY MASS INDEX DOES NOT IMPACT CLINICAL EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE IM-UNITI TRIAL

IBD (Posters)  et al.

NOVEL APPROACH TO BIND AND SPECIFICALLY DETECT FIMH-EXPRESSING E. COLI USING HEPTYLMANNOSE-FUNCTIONALIZED CELLULOSE IN THE CONTEXT OF CROHN'S DISEASE
NOVEL APPROACH TO BIND AND SPECIFICALLY DETECT FIMH-EXPRESSING E. COLI USING HEPTYLMANNOSE-FUNCTIONALIZED CELLULOSE IN THE CONTEXT OF CROHN'S DISEASE

IBD (Posters)  et al.

COLONIC ORGANOIDS FOR THE INVESTIGATION OF CLINICAL RESPONSIVENESS TO ANTI-TUMOR NECROSIS FACTOR AGENTS IN PATIENTS WITH ULCERATIVE COLITIS
COLONIC ORGANOIDS FOR THE INVESTIGATION OF CLINICAL RESPONSIVENESS TO ANTI-TUMOR NECROSIS FACTOR AGENTS IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

SHORT DISEASE DURATION AND SUPERFICIAL PENETRATION WITHIN THE ILEAL WALL ARE ASSOCIATED TO M1 MACROPHAGES INFILTRATION AND ACTIVATION IN ILEOCOLONIC CROHN´S DISEASE
SHORT DISEASE DURATION AND SUPERFICIAL PENETRATION WITHIN THE ILEAL WALL ARE ASSOCIATED TO M1 MACROPHAGES INFILTRATION AND ACTIVATION IN ILEOCOLONIC CROHN´S DISEASE

IBD (Posters)  et al.

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

IBD (Posters)  et al.

ENDOSCOPIC AND HISTOLOGIC REMISSION IN TOFACITINIB TREATED REFRACTORY MODERATE-TO-SEVERE PATIENTS WITH ULCERATIVE COLITIS: A PROSPECTIVE REAL-LIFE COHORT
ENDOSCOPIC AND HISTOLOGIC REMISSION IN TOFACITINIB TREATED REFRACTORY MODERATE-TO-SEVERE PATIENTS WITH ULCERATIVE COLITIS: A PROSPECTIVE REAL-LIFE COHORT

IBD (Posters)  et al.

PREDICTING TOFACITINIB INDUCED ENDOSCOPIC RESPONSE IN ULCERATIVE COLITIS THROUGH A MUCOSAL BIOMARKER
PREDICTING TOFACITINIB INDUCED ENDOSCOPIC RESPONSE IN ULCERATIVE COLITIS THROUGH A MUCOSAL BIOMARKER

IBD (Posters)  et al.

VACCINES AND IMMUNIZATION STATUS IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE. EVALUATION AT DIAGNOSIS
VACCINES AND IMMUNIZATION STATUS IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE. EVALUATION AT DIAGNOSIS

IBD (Posters)  et al.

IDENTIFICATION OF RELEVANT PATIENT REPORTED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - LISTEN I
IDENTIFICATION OF RELEVANT PATIENT REPORTED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - LISTEN I

IBD (Posters)  et al.

CONTINUATION OF ANTI-TNF IN PATIENTS WITH ULCERATIVE COLITIS IN REMISSION IS NOT COST-EFFECTIVE COMPARED TO TREATMENT WITHDRAWAL: A MARKOV MODEL
CONTINUATION OF ANTI-TNF IN PATIENTS WITH ULCERATIVE COLITIS IN REMISSION IS NOT COST-EFFECTIVE COMPARED TO TREATMENT WITHDRAWAL: A MARKOV MODEL

IBD (Posters)  et al.

Item 21 - 40 / 279
1
2
3 4 5 6 7 8 9 10 11 12 13 14